Hurley Capital
RXRX icon

Hurley Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Hurley Capital’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.51K Hold
850
– – ﹤0.01% 499
2026
Q2 		$3.12K Hold
850
– – ﹤0.01% 515
2026
Q1 		$2.61K Hold
850
– – ﹤0.01% 546
2025
Q4 		$3.48K Buy
+850
New +$4.21K ﹤0.01% 477

Other funds holding RXRX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
MIC Capital Management (UK)
MIC Capital Management (UK) London, United Kingdom $463M AUM 7.9% 1-Year Est. Return

Hurley Capital's RXRX Position: Q3 2026 in Review

Hurley Capital held its Recursion Pharmaceuticals (RXRX) position steady in Q3 2026 at 850 shares worth $3.51K. The position accounts for ﹤0.01% of the portfolio, ranked #499.

Hurley Capital first reported a position in RXRX in Q4 2025 and has held it in 4 quarters since. 264 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • Hurley Capital held 850 shares of Recursion Pharmaceuticals worth $3.51K as of Q3 2026.
  • Hurley Capital left its Recursion Pharmaceuticals share count unchanged in Q3 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Hurley Capital's portfolio in Q3 2026, its #499 holding.
  • Hurley Capital first reported a position in Recursion Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • 264 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on Hurley Capital's 13F filing for Q3 2026, filed 5 Nov 2026.